Patent Application
20120245078
This invention relates to a combination of (a) at least one glucocorticoid; and (ba) at least one proteasome inhibitor and/or (bb) at least one nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation, for use in the treatment or prevention of ischemic disorders of the central nervous system.
In this specification, a number of documents including patent applications and manufacturer's manuals is cited. The disclosure of these documents, while not considered relevant for the patentability of this invention, is herewith incorporated by reference in its entirety. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
Disruption of the blood-brain barrier (BBB) and concomitant edema formation are pathological hallmarks of various disorders of the central nervous system. The BBB is formed by brain capillary endothelial cells (Rubin (1999)). Tight junctions are important structural components of the BBB which seal the paracellular space between brain microvascular endothelial cells and thereby restrict paracellular permeability (Förster (2008), Wolburg (2002)). Among the tight junction proteins expressed at the BBB, the transmembrane proteins occludin and claudin-5 have been shown to be critical for sealing the paracellular space (D'Atri (2002)) and degradation of these proteins is involved in BBB breakdown during multiple sclerosis, meningitis or brain neoplasm (rev. in Förster (2008)). The impact of focal cerebral ischemia on the expression of tight junction proteins has only recently begun to be addressed. Localization of claudin-5 in the plasma membrane and expression of claudin-5 protein was altered under hypoxic conditions in mouse brain bEND.3 cells (Kato (2007)). This was accompanied by a decrease in transendothelial resistance. Kago and co-workers (Kago (2006)) investigated the expression of occludin and zonula occludens (ZO)-1 in isolated brain capillaries ex vivo and found downregulation after microsphere-induced cerebral embolism.
While glucocorticoids (GC) potently stabilize the BBB and diminish tissue edema in neuroinflammatory diseases (e.g. multiple sclerosis) or brain tumors, these substances are ineffective or even harmful when applied for the treatment of acute ischemic stroke (Norris (2004), Norris (1986), Poungvarin (2004), De Reuck (1988), Kumar (1989)). The biological effects of glucocorticoids are mediated by the glucocorticoid receptor (GR) (Beato (1989)). The GR is a member of the nuclear receptor superfamily and binds to specific DNA sequences (glucocorticoid-response element, GRE) in the 5′-flanking region of target genes thereby activating gene transcription (Beato (1989), Stoll (2000)). It is expressed in a wide range of tissues including vascular endothelium, and GR expression levels correlate with its transcriptional activity.
The ubiquitin-proteasome system controls the intracellular levels of short-lived and regulatory proteins, which are important for a variety of basic cellular processes.
WO 98/35691 A1 describes methods for treating an ischemic injury comprising the administration of an inhibitor of NF-
In view of the limitations of the methods described in the prior art, the technical problem underlying the present invention was therefore the provision of alternative or improved means and methods for treating ischemic conditions.
Accordingly, this invention relates to a combination of (a) at least one glucocorticoid; and (ba) at least one proteasome inhibitor and/or (bb) at least one nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation, for use in the treatment or prevention of ischemic disorders of the central nervous system.
The term “combination” in conjunction with the recited treatment refers to the combined administration of at least two of the recited agents to a patient in need thereof. To explain further, the following combinations are envisaged: (i) at least one glucocorticoid and at least one proteasome inhibitor; (ii) at least one glucocorticoid and at least one nucleic acid as defined above; (iii) at least one glucocorticoid, at least one proteasome inhibitor and at least one nucleic acid as defined above. It is preferred to combine at least one glucocorticoid and at least one proteasome inhibitor. It is more preferred to combine one glucocorticoid and one proteasome inhibitor. Preferred glucocorticoids and preferred proteasome inhibitors are described below.
It is furthermore envisaged that at least one further pharmaceutically active agent is included in the combination. In a preferred embodiment, the combination does not include any such further pharmaceutically active agent.
The term “glucocorticoid” is known in the art and refers to a subclass of steroid hormones the members of which are characterized in that they bind the glucocorticoid receptor. The use of glucocorticoids in medicine is well established. They are used to treat diseases that are caused by an overactive immune system, such as allergies, asthma, autoimmune diseases and sepsis. They also interfere with some of the abnormal mechanisms in cancer cells, so they are used in high doses to treat cancer. In the latter case, glucocorticoids are used to drive cells, in particular malignant cells, into apoptosis. This effect is fundamentally different from the effect of glucocorticoids as exploited by the present invention which is confining damage to cells, the damage being caused by ischemia. As stated above, the art advises against the use of glucocorticoids in the treatment of ischemic conditions of the central nervous system. Preferred glucocorticoids are described further below.
The term “proteasome” is known in the art and refers to a macromolecular assembly capable of proteolytically degrading polypeptides and proteins. Proteasomes are found in all eukaryotes. Proteasomes are part of a major mechanism by which cells regulate the concentration of particular proteins and degrade misfolded proteins. The degradation process yields peptides of about seven to eight amino acids long, which can then be further degraded into amino acids and used in synthesizing new proteins. Proteins are tagged for degradation by a small protein called ubiquitin. The tagging reaction is catalyzed by enzymes called ubiquitin ligases. Once a protein is tagged with a single ubiquitin molecule, this is a signal to other ligases to attach additional ubiquitin molecules. The result is usually a polyubiquitin chain that is subsequently bound by the proteasome, allowing it to degrade the tagged protein. Structure and constituent proteins of the proteasome are known in the art and described, for example, in Finley (2009). In brief, the proteasome as a whole, also referred to as 26S-proteasome holoenzyme, typically comprises two 19S regulatory particles and one 20S catalytic core. The 20S catalytic core contains 14 distinct subunits: α1, α2, α3, α4, α5, α6, α7, β1, β2, β3, β4, β5, β6, β7. A 19S regulatory particle (19 subunits in total) contains lid and base subcomplexes. The lid subcomplex contains 9 subunits: PSMD3, PSMD12, PSMD11, PSMD6, PSMD7, PSMD4, PSMD14, PSMD8, and PSMD9, and the base subcomplex contains 10 subunits: PSMC2, PSMC1, PSMC4, PSMC6, PSMC3, PSMC5, PSMD2, PSMD1, PSMD4, and ADRM1
A “proteasome inhibitor” is a compound which interferes with the above described capability of the proteasome to degrade polypeptides and proteins. Generally speaking, the term “inhibitor” designates a compound lowering the activity of a protein, preferably by performing one or more of the following effects: (i) the transcription of the gene encoding the protein to be inhibited is lowered, (ii) the translation of the mRNA encoding the protein to be inhibited is lowered, (iii) the protein performs its biochemical function with lowered efficiency in presence of the inhibitor, and (iv) the protein performs its cellular function with lowered efficiency in presence of the inhibitor. In this context, the term “protein” refers to any of the constituent proteins of the proteasome.
Compounds falling in class (i) include compounds interfering with the transcriptional machinery and/or its interaction with the promoter of said gene and/or with expression control elements remote from the promoter such as enhancers. Compounds of class (ii) comprise antisense constructs and constructs for performing RNA interference well known in the art. Compounds of class (iii) interfere with molecular function of the protein to be inhibited, in case of the proteasome preferably with its enzymatic activity. Accordingly, active site binding compounds are envisaged. More preferred are compounds specifically binding to an active site of the proteasome. Also envisaged are compounds binding to or blocking substrate binding sites of the proteasome as are compounds binding to or blocking binding sites involved in proteasome assembly. Class (iv) includes compounds which do not necessarily directly bind to the proteasome, but still interfere with proteasome activity, for example by binding to and/or inhibiting the function or inhibiting expression of members of a pathway which comprises the proteasome. These members may be either upstream or downstream of the proteasome within said pathway. Preferred members are members of the ubiquitination pathway and are further detailed below.
In a preferred embodiment, the inhibitor is a low molecular weight compound. Low molecular weight compounds are compounds of natural origin or chemically synthesized compounds, preferably with a molecular weight between 100 and 1000, more preferred between 200 and 750, and even more preferred between 300 and 600. Preferred low molecular weight compound are small organic molecules. An organic molecule is a molecule comprising a carbon skeleton an optionally one or more heteroatoms, preferably selected from O, N, S and P.
The efficiency of the inhibitor can be quantitized by comparing the level of activity in the presence of the inhibitor to that in the absence of the inhibitor. For example, as an activity measure may be used: the change in amount of mRNA formed, the change in amount of protein formed, the change in amount of substrate converted or product formed, and/or the change in the cellular phenotype or in the phenotype of an organism.
In a preferred embodiment, the level of activity is less than 90%, more preferred less than 80%, 70%, 60% or 50% of the activity in absence of the inhibitor. Yet more preferred are inhibitors lowering the level down to less than 25%, less than 10%, less than 5%, less than 1%, less than 0.1%, less than 0.01% or less than 0.001% of the activity in absence of the inhibitor.
Preferred structural classes of proteasome inhibitors are described further below.
The intended use of the nucleic acid according to the main embodiment falls into the domain of gene therapy. Gene therapy is the introduction of nucleic acids encoding a beneficial gene product into an individual in need of the beneficial effects elicited by said gene product. The typical scenario is an individual carrying a deleterious mutation in the gene at issue and receiving an intact form of the gene. In the context of the present invention, however, it is the wild type glucocorticoid receptor which has disadvantageous properties in that it is amenable to proteasomal degradation; see further below. By making available a glucocorticoid receptor which is resistant to proteasomal degradation, this deficiency is overcome.
Constructs for gene therapy are well known in the art and familiar to the skilled person. Constructs for gene therapy generally comprise (i) the therapeutic agent which is a nucleic acid and which usually is to be delivered to a target site, target cell and/or target tissue and, optionally, (ii) an agent which enables or facilitates delivery to said target site, target cell and/or target tissue such that the therapeutic effect may occur, is enhanced, or occurs predominantly or only at the target site. For example, the nucleic acid to be delivered may be comprised in a vector, preferably a viral vector. Viral vectors for gene therapy include retroviruses, adenoviruses, and adeno-associated viruses. Furthermore, many vectors have been developed in which the endogenous viral envelope proteins have been replaced by either envelope proteins from other viruses, or by chimeric proteins. Such chimera consist of those parts of the viral protein necessary for incorporation into the virion as well as sequences meant to interact with specific host cell proteins. Viruses in which the envelope proteins have been replaced as described are referred to as pseudotyped viruses. The above described procedure is also referred to as envelope protein pseudotyping of viral vectors. Another type of constructs for gene therapy are lipoplexes and polyplexes. A lipoplex is a liposome complexed with nucleic acid. Polyplexes are complexes of polymers, preferably cationic polymers with nucleic acid. Lipoplexes and polyplexes protect the nucleic acid from undesirable degradation during the transfection process.
Under certain conditions component (i) alone may suffice and constitute the construct for gene therapy according to the invention. Examples are naked nucleic acids, preferably comprised in buffered solution.
The term “nucleic acid” as used herein refers to all forms of nucleic acids, in particular to DNA, such as cDNA or genomic DNA, and RNA. It is understood that the term “RNA” as used herein comprises all forms of RNA including mRNA.
The term “glucocorticoid receptor” is well established in the art and discussed in the introductory section herein above. The glucocorticoid receptor (GR), also known as NR3C1 (nuclear receptor subfamily 3, group C, member 1), is the receptor that glucocorticoids bind to. The glucocorticoid receptor according to item (bb) of the main embodiment is modified as compared to the wild type receptor in that it is not, or only to a reduced degree, amenable to proteasomal degradation. A reduced degree of degradability includes less than 25%, less than 10%, less than 5%, less than 1%, less than 0.1%, less than 0.01% or less than 0.001% degraded GR as compared to wild type GR, preferably of the same species, degraded under the same conditions. Nucleic acid and protein sequence of the glucocorticoid receptor from a plurality of species, including mammalian species, are available from the sequence databases available at, for example, the National Center for Biotechnology Information (NCBI) at the NIH and the European Bioinformatics Institute (EBI) of the EMBL. Just to give an example, entry P04150 (GCR_HUMAN) of the SwissProt database (version 152 of Sep. 1, 2009) provides a curated annotated amino acid sequence of the human glucocorticoid receptor.
The term “ischemic disorder” is known in the art and refers to conditions arising from a restriction in blood supply, generally due to factors in the blood vessels, with resultant damage or dysfunction of tissue.
The term “central nervous system”, abbreviated “CNS”, as used herein has its established meaning and refers to the brain and the spinal chord.
The present invention results from the surprising discovery that proteasomal degradation is responsible for the glucocorticoid insensitivity observed in patients suffering from ischemic disorders of the CNS; see the enclosed examples. It turns out that proteasomal degradation of the glucocorticoid receptor is specific for vascular endothelial cells. While glucocorticoid insensitivity in ischemic disorders of the CNS as such is an established fact, there is no remedy described in the art, the consequence being that the use of glucocorticoid is discouraged for these indications. The present invention makes glucocorticoid therapy available for such patients, wherein concomitant with such therapy glucocorticoid sensitivity is restored. Envisaged means for restoring glucocorticoid sensitivity are basically any means suitable to that effect, in particular the means according to items (ba) and (bb) of the main embodiment. The envisaged therapeutic approach is supported by the enclosed examples which include both in vitro and in vivo evidence. In particular, the capability of glucocorticoids to induce tight junction proteins at the blood brain barrier is restored upon interfering with the proteasomal degradation of the glucocorticoid receptor. While administration of only one of the constituents according to the combination of the main embodiment does not significantly ameliorate the symptoms of ischemic disorder, the combination does. Accordingly, the combinations according to the present invention are characterized in that they exhibit a synergistic effect; see the enclosed examples.
It is understood that by treating or preventing ischemic disorders of the central nervous systems, disorders which may arise in consequence of an ischemic disorder are also treated or prevented. Such disorders which may arise in consequence of an ischemic disorder include neurological disorders.
In a preferred embodiment, the glucocorticoid is selected from dexamethasone, methylprednisolone and cortisol. Another envisaged glucocorticoid is betamethasone. More preferred glucocorticoids are dexamethasone and methylprednisolone. Particularly preferred is methylprednisolone.
It established in the art, that different glucocorticoids, when administered as the sole pharmaceutically active agent, have different efficacy. For example, dexamethasone is known to be thirty times as potent as cortisol and approximately six times as potent as methylprednisolone. These known ratios between the potencies of the specific glucocorticoids have been taken into account when performing the experiments described in the examples enclosed herewith. In particular, dosages have been chosen which are described in the art as “equivalent dosages”, i.e., dosages known to trigger comparable effects. Even though equivalent doses of the three GC were administered, efficacy surprisingly turned out to vary: the combination therapy with dexamethasone and bortezomib was most effective and consistent in reduction of stroke volume, edema volume and preservation of global neurological function. While the combination of methylprednisolone plus bortezomib had pronounced effects on edema volume, reduction of overall stroke volume and neurological damage was somewhat less effective as compared to dexamethasone. Both dexamethasone and methylprednisolone surprisingly performed superior when compared to cortisol. In other words, the preferred embodiments relating to the use of methylprednisolone and in particular of dexamethasone are characterized by a surprising advantageous technical effect which could not be predicted from the prior art.
In a further preferred embodiment, the proteasome inhibitor is selected from peptide boronic acids and esters thereof, lactacystin and analogs thereof, and peptide aldehydes. These compound classes are well known in the art as is their capability of inhibiting proteasome activity. They are inter alia described in WO 98/35691 A1 (cited above), which is incorporated by reference in its entirety. Particularly relevant is passage from page 11, bottom to page 12, line 22 of WO 98/35691 A1, which is reproduced in the following: Non-limiting examples of proteasome inhibitors for use in the present invention include peptide aldehydes (Stein et al. WO 95/24914 published Sep. 21, 1995; Siman et al. WO 91/13904 published Sep. 19, 1991; Iqbal et al. J. Med. Chem. 38:2276-2277 (1995)), peptide boronic acids (Adams et al. WO 96/13266 published May 9, 1996; Siman et al. WO 91/13904), lactacystin, and lactacystin analogs (Fenteany et al. Proc. Natl. Acad. Sci. USA (1994) 91:3358; Fenteany et al. WO 96/32105, published Oct. 17, 1996). Peptide aldehyde proteasome inhibitors for use in the present invention preferably are those disclosed in Stein et al. WO 95/24914 published Sep. 21, 1995 or Siman et al. WO 91/13904 published Sep. 19, 1991, both hereby incorporated by reference in their entirety. Boronic acid or ester compounds for use in the present invention preferably are those disclosed in Adams et al. WO 96/13266 published May 9, 1996, or Siman et al. WO 91/13904, both of which are hereby incorporated by reference in their entirety. More preferably, the boronic acid compound for use in the present invention is selected from the group consisting of: N-(4-morpholine)carbonyl-β-(1-naphthyl)-L-alanine-L-leucine boronic acid; N-(8-quinoline)sulfonyl-β-(1-naphthyl)-L-alanine-L-alanine-L-leucine boronic acid; N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid, and N-(4-morpholine)carbonyl-[O-(2-pyridylmethyl]-L-DR-tyrosine-L-leucine boronic acid. Lactacystin and lactacystin analog compounds for use in the present invention preferably are those disclosed in Fenteany et al. WO 96/32105, published Oct. 17, 1996, hereby incorporated by reference in its entirety. More preferably, the lactacystin analog is selected from lactacystin, clasto-lactacystin β-lactone, 7-ethyl-clasto-lactacystin β-lactone and 7-n-propyl-clasto-lactacystin β-lactone. Most preferably the lactacystin analog is 7-n-propyl-clasto-lactacystin β-lactone.
A preferred peptide aldehyde also known as calpain inhibitor I (N-acetyl-Leu-Leu-Nle-CHO) is one of the proteasome inhibitors used in the examples.
In a particularly preferred embodiment, the proteasome inhibitor is bortezomib. Bortezomib (systematic name: [(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid), also known as Velcade®, is a well-known proteasome inhibitor, which has been approved for the monotherapy of certain malignant diseases.
In particularly preferred embodiments of the present invention, the proteasome inhibitor is bortezomib and the glucocorticoid is selected from dexamethasone and methylprednisolone. Most preferred is the combination of bortezomib and dexamethasone. In these embodiments it is preferred that no further pharmaceutically active agent is comprised or used.
Further proteasome inhibitors according to the invention are RNAi agents, antisense molecules, ribozymes, antibodies and aptamers directed against one or more constituent proteins of the proteasome or nucleic acids encoding said constituent proteins, respectively.
The term “RNAi agent” refers to molecules capable of triggering RNA interference, RNA interference being a sequence-specific gene silencing process (see, e.g. Zamore Nat Struct Biol 2001, 8(9):746-50; Tuschl T. CHEMBIOCHEM. 2001, 2:239-245; Scherr and Eder, Cell Cycle. 2007 February; 6(4):444-9; Leung and Whittaker, Pharmacol Ther. 2005 August; 107(2):222-39; de Fougerolles et al., Nat. Rev. Drug Discov. 2007, 6: 443-453). “RNAi agents” include “small interfering RNAs” (siRNAs), which are a class of generally short and double-stranded RNA molecules that play a variety of roles in biology and, to an increasing extent, in treatment of a variety of diseases and conditions. Such siRNAs are generally 18-27 nt long, generally comprising a short (usually 19-21-nt) double-strand of RNA (dsRNA) with or without 2-nt 3′ overhangs on either end. Each strand can have a 5′ phosphate group and a 3′ hydroxyl (—OH) group or the phosphate group can be absent on one or both strands. This structure is the result of processing by Dicer, an enzyme that converts either long dsRNAs or small hairpin RNAs into siRNAs.
RNAi agents can also be exogenously (artificially) introduced into cells by various transfection methods to bring about the specific knockdown of a gene of interest. In this context, other structures than those described above are also envisaged, provided they are capable of interfering with gene expression. Preferred are double-stranded RNAs (dsRNAs), the double-stranded part of which has a length of about 12 to about 50 base pairs. The term “dsRNA” includes siRNAs. The dsRNA of the invention may either have overhanging sequences of up to 10 bases, preferably not more than 5 bases in length at either end or at one end, or may be blunt-ended. Also preferred is that the complementarity to the target gene extends over the entire length of the double-stranded part. The region which is complementary to the target gene is at least 12 bases, preferably at least 15, 16, 17, 18, 19, 20, 21, 22, 23 or more bases in length. The siRNA of the invention may be fully complementary to the target gene. Alternatively, the dsRNA may comprise up to 5%, 10%, 20% or 30% mismatches to the target gene. Furthermore, dsRNAs (and also antisense molecules) can be chemically modified e.g. on the backbone including the sugar residues. Preferred modifications of the dsRNA molecules of the invention include linkers connecting the two strands of the siRNA molecule. Chemical modifications serve inter alia to improve the pharmacological properties of siRNAs and antisense molecules such as in vivo stability and/or delivery to the target site within an organism. The skilled person is aware of such modified dsRNAs as well as of means and methods of obtaining them, see, for example, Zhang et al., Curr Top Med. Chem. 2006; 6(9):893-900; Manoharan, Curr Opin Chem. Biol. 2004 December; 8(6):570-9.
Essentially any gene of which the sequence is known can thus be targeted based on sequence complementarity with an appropriately tailored dsRNA. This has made dsRNAs an important tool for gene function and drug target validation studies as well as for therapeutic intervention which is envisaged here. The dsRNAs of the present invention are capable of reducing or blocking expression of the proteins and nucleic acids defined herein above.
The term “antisense molecule” or “antisense construct” is known in the art and refers to a nucleic acid which is complementary to a target nucleic acid. An antisense molecule according to the invention is capable of interacting with, more specifically hybridizing with the target nucleic acid. By formation of the hybrid, transcription of the target gene(s) and/or translation of the target mRNA is reduced or blocked. Standard methods relating to antisense technology have been described (see, e.g., Melani et al., Cancer Res. (1991) 51:2897-2901). Ribozymes are enzymes consisting of or comprising a catalytically active ribonucleic acid which in turn comprises a sequence complementary to a sequence in the target nucleic acid. Ribozymes specifically cleave the target nucleic acid, such as the (pre)-mRNA of a gene, the consequence being reduction or repression of expression. The techniques underlying said repression of expression are well known in the art (see, e.g., EP-B1 0 291 533, EP-A10 321 201, EP-A2 0 360 257). Selection of appropriate target sites and corresponding ribozymes can be done as described for example in Steinecke et al. (Methods in Cell Biology (1995) 50:449-460).
The term “antibody” includes monoclonal antibodies, polyclonal antibodies, single chain antibodies, or fragments thereof that specifically bind said peptide or polypeptide, also including bispecific antibodies, synthetic antibodies, antibody fragments, such as Fab, a F(ab2)′, Fv or scFv fragments etc., or a chemically modified derivative of any of these. Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, Nature 256 (1975), 495, and Galfré, Meth. Enzymol. 73 (1981), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals with modifications developed by the art. Furthermore, antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane “Antibodies, A Laboratory Manual”, CSH Press, Cold Spring Harbor, 1988. When derivatives of said antibodies are obtained by the phage display technique, surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies which bind to an epitope of the abovementioned protein (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13). The production of chimeric antibodies is described, for example, in WO89/09622. A further source of antibodies to be utilized in accordance with the present invention are so-called xenogenic antibodies. The general principle for the production of xenogenic antibodies such as human antibodies in mice is described in, e.g., WO 91/10741, WO 94/02602, WO 96/34096 and WO 96/33735. Antibodies to be employed in accordance with the invention or their corresponding immunoglobulin chain(s) can be further modified using conventional techniques known in the art, for example, by using amino acid deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) known in the art either alone or in combination. Methods for introducing such modifications in the DNA sequence underlying the amino acid sequence of an immunoglobulin chain are well known to the person skilled in the art; see, e.g., Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989. The term “monoclonal” or “polyclonal antibody” (see Harlow and Lane, (1988), loc. cit.) also relates to derivatives of said antibodies which retain or essentially retain their binding specificity. Whereas particularly preferred embodiments of said derivatives are specified further herein below, other preferred derivatives of such antibodies are chimeric antibodies comprising, for example, a mouse or rat variable region and a human constant region. The term “scFv fragment” (single-chain Fv fragment) is well understood in the art and preferred due to its small size and the possibility to recombinantly produce such fragments. Preferably, the antibody, aptamer (see further below), fragment or derivative thereof according to the invention specifically binds the target protein, (poly)peptide or fragment or epitope thereof whose presence or absence is to be monitored. The term “specifically binds” in connection with the antibody used in accordance with the present invention means that the antibody etc. does not or essentially does not cross-react with (poly)peptides of similar structures. Cross-reactivity of a panel of antibodies etc. under investigation may be tested, for example, by assessing binding of said panel of antibodies etc. under conventional conditions (see, e.g., Harlow and Lane, (1988), loc. cit.) to the protein of interest as well as to a number of more or less (structurally and/or functionally) closely related proteins. Only those antibodies that bind to the protein of interest but do not or do not essentially bind to any of the other proteins which are preferably expressed by the same tissue as the protein of interest, are considered specific for the protein of interest. In a particularly preferred embodiment of the method of the invention, said antibody or antibody binding portion is or is derived from a human antibody or a humanized antibody. The term “humanized antibody” means, in accordance with the present invention, an antibody of non-human origin, where at least one complementarity determining region (CDR) in the variable regions such as the CDR3 and preferably all 6 CDRs have been replaced by CDRs of an antibody of human origin having a desired specificity. Optionally, the non-human constant region(s) of the antibody has/have been replaced by (a) constant region(s) of a human antibody. Methods for the production of humanized antibodies are described in, e.g., EP-A10 239 400 and WO90/07861.
Aptamers are nucleic acid molecules that have been selected from random pools based on their ability to bind other molecules. Aptamers have been selected which bind nucleic acid, proteins, small organic compounds, and even entire organisms.
In a further preferred embodiment, the ischemic disorder of the central nervous system is a cerebral ischemic disorder or a spinal chord ischemia. Furthermore preferred is that the ischemic disorder of the central nervous system is selected from disruption of the blood brain barrier, cerebral infarct, cerebral stroke, brain edema, hypoxic conditions accompanying traumatic brain injury, ischemic conditions occurring in premature babies, brain hypoperfusion, embolic brain ischemia and thrombotic brain ischemia. Ischemic disorders in general are characterized in that they entail glucose and or oxygen deprivation (hypoxia) of the affected tissue. In the central nervous system, both glucose deprivation and/or hypoxia may lead to leakiness of the blood brain barrier by a mechanism which has been investigated by the present inventors and is described in more detail in the examples. In brief, it is demonstrated that occludin and claudin-5 are significantly reduced in murine brain-derived cEND cells upon hypoxia which leads to an increase in transendothelial permeability. Moreover, several other components of the junctional complex in brain endothelial cells such as claudin-3, -12 and VE-cadherin are likewise altered underlining that hypoxia has a critical impact on the structure of the neurovascular interface.
The term “blood brain barrier” is known in the art and refers to a separation of circulating blood and cerebrospinal fluid maintained by the choroid plexus in the central nervous system. Endothelial cells restrict the diffusion of microscopic objects (e.g. bacteria) and large or hydrophilic molecules into the cerebrospinal fluid, while allowing the diffusion of certain small molecules (such as O2, hormones, CO2). Cells of the barrier actively transport specific compounds such as glucose across the barrier with specific proteins.
The medical indications amenable to treatment according to the present invention include the ischemic conditions arising from stroke or infarct as defined above. The indications furthermore include ischemic/hypoxic conditions as they typically arise in prematurely born babies, in particular those with particularly low birth weight as well as in cases of traumatic brain injury. Prematurely born babies with particularly low birth weight include those with a birth weight below 1700 g.
In a preferred embodiment, the glucocorticoid is to be administered prior to, concomitantly with or after the proteasome inhibitor and/or the nucleic acid. It is understood that in those embodiments wherein the glucocorticoid is to be administered prior to or after the proteasome inhibitor, the time interval between the administration of the two agents is to be chosen such that the above described synergistic effect can occur. For example, at the point in time of the administration of a glucocorticoid following an earlier administration of a proteasome inhibitor, the amount of glucocorticoid receptor available for glucocorticoid signalling is elevated as compared to control subjects which have not been treated with a proteasome inhibitor.
Accordingly, it is preferred that the time interval between administration of the glucocorticoid and of the proteasome inhibitor and/or nucleic acid is not to exceed 48, 24, 12, 6, 3, or 0 hours. The time intervals are listed by increasing preference, i.e., 0 hours is the most preferred value.
The concomitant administration may be effected by administering a single dosage form which comprises both the glucocorticoid and the proteasome inhibitor and/or the nucleic acid. Alternatively, a single dosage form comprising the glucocorticoid and a separate single dosage form comprising the proteasome inhibitor and/or the nucleic acid may be administered concomitantly. Those embodiments where the glucocorticoid is to be administered prior to or after the proteasome inhibitor are typically effected by administering a single dosage form comprising the glucocorticoid and a single dosage form comprising the proteasome inhibitor and/or the nucleic acid at different points in time. In other words, the combination according to the invention implies one or more pharmaceutical compositions for use in the treatment of ischemic disorders of the central nervous system, the pharmaceutically active agents comprised in the pharmaceutical composition(s) being as defined above.
The recited administration may be performed once or repeatedly, dependent on the severity of the disorder and the needs of the patient. The patient may be a human or an animal. Preferred animals are mammals.
The pharmaceutical composition(s) will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient, the site of delivery of the pharmaceutical composition, the method of administration, the scheduling of administration, and other factors known to practitioners. The “effective amount” of the pharmaceutical composition for purposes herein is thus determined by such considerations.
The skilled person knows that the effective amount of pharmaceutical composition administered to an individual will, inter alia, depend on the nature of the compound. For example, the total pharmaceutically effective amount of pharmaceutical composition administered parenterally per dose may be in the range of about 1 μg kg−1 day−1 to 10 mg kg−1 day−1 of patient body weight, although, as noted above, this may be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg kg−1 day−1, and most preferably for humans between about 0.01 and 1 mg kg−1 day−1. A preferred single or daily dose of dexamethasone for an adult is between 0.5 and 24 mg, more preferred between 0.5 and 8 mg, 0.5 and 4 mg and particularly preferred between 0.5 and 1.5 mg. A preferred single or daily dose of bortezomib is between 1 and 2 mg m−2 body surface, 1.3 mg m−2 body surface being a preferred value. If given continuously, the pharmaceutical composition is typically administered at a dose rate of about 1 μg kg−1 hour−1 to about 50 μg kg−1 hour−1, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect. The particular amounts may be determined by conventional tests which are well known to the person skilled in the art.
Pharmaceutical compositions of the invention may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray. The term “parenteral” as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
Pharmaceutical compositions of the invention preferably comprise a pharmaceutically acceptable carrier. By “pharmaceutically acceptable carrier” is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
The pharmaceutical composition is also suitably administered by sustained release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al., Id.) or poly-D-(−)-3-hydroxybutyric acid (EP 133,988). Sustained release pharmaceutical composition also include liposomally entrapped compound. Liposomes containing the pharmaceutical composition are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. (USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal therapy.
For parenteral administration, the pharmaceutical composition is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
Generally, the formulations are prepared by contacting the components of the pharmaceutical composition uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes. The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) (poly)peptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.
The components of the pharmaceutical composition to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic components of the pharmaceutical composition generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
The components of the pharmaceutical composition ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous solution, and the resulting mixture is lyophilized. The solution for infusion or injection is prepared by reconstituting the lyophilized compound(s) using bacteriostatic water for injection.
Preferably, at least the glucocorticoid or at least the proteasome inhibitor and/or the nucleic acid is to be administered within 48, 24, 12, 6, 3, or 0 hours from the ischemic event. The time intervals are listed by increasing preference, i.e., 0 hours is the most preferred value. The term “ischemic event” refers to the point in time where the blockage or reduction in blood flow which is causative of the ischemic disorder occurred.
The present invention furthermore relates to at least one proteasome inhibitor and/or at least one nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation, for use in treating or preventing glucocorticoid resistance in ischemic disorders of the central nervous system. In this embodiment, the invention provides means for restoring glucocorticoid sensitivity in ischemic disorders of the central nervous system by counteracting proteasomal glucocorticoid receptor degradation and/or by providing a nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation. By restoring glucocorticoid sensitivity, the administration of glucocorticoids, otherwise not recommendable for ischemic disorders of the central nervous system, becomes a treatment option. In preferred embodiments, only one proteasome inhibitor and/or only one nucleic acid are used. More preferred is the use of one proteasome inhibitor or only one nucleic acid. Even more preferred is the use of one proteasome inhibitor.
Preferred embodiments of the proteasome inhibitor as well as of the recited ischemic disorder are defined herein above. A particularly preferred proteasome inhibitor is bortezomib.
In preferred embodiments, of the combination or the at least one nucleic acid according to the invention, said glucocorticoid receptor being resistant to proteasomal degradation is a glucocorticoid receptor wherein residues important for ubiquitin conjugation are mutated such that ubiquitin conjugation is abolished or substantially decreased. “Substantially decreased” includes less than 25%, less than 10%, less than 5%, less than 1%, less than 0.1%, less than 0.01% or less than 0.001% ubiquitin conjunction as compared to the wild type GR, preferably from the same species. As described above, the proteasomal pathway involves the tagging of proteins for degradation. This tagging is effected by covalently linking an ubiquitin molecule to a molecule of the protein to be degraded, usually followed by covalently linking a further ubiquitin molecule to ubiquitin molecule attached to the protein to be degraded, and so on, thereby giving rise to polyubiquitin chain(s) attached to the protein to be degraded. Typical attachment sites on the target molecule for the first ubiquitin molecule are lysine residues. Mutating or deleting lysine residues is therefore a preferred option for rendering a protein less amenable to proteasomal degradation. Whether and to which extent a given mutation or deletion has the desired effect, can be determined by the skilled person without further ado, for example, by comparing the protein levels in cells transfected with the nucleic acid according to the invention as compared to untransfected controls. Determining protein levels can be performed with established methods such as Western blotting or immunoprecipitation.
It also envisaged to target other components of the proteasomal pathway, for example the enzymes involved in the process of ubiquitination (reviewed in Kinyamu (2005)), also known as ubiquitin ligases or E3 enzymes. The ubiquitin ligases generally are substrate-specific to a higher degree than the ubiquitin-conjugating enzymes (E2 enzymes) and the ubiquitin-activating enzymes (E1 enzymes) which are also part of the ubiquitination pathway, the ubiquitination pathway in turn being part of the proteasomal pathway according to the present invention. Accordingly, ubiquitin ligases, but also E1 and E2 enzymes are deliberately envisaged targets for interfering with proteasomal degradation of the glucocorticoid receptor. Inhibitors of E1, E2 and/or E3 enzymes are proteasome inhibitors in the sense of the above defined class (iv) of inhibitors.
In preferred embodiments of the invention, said glucocorticoid receptor being resistant to proteasomal degradation is (i) a mutant of the human glucocorticoid receptor, the mutant differing from the wild type in that K419 is replaced with a different amino acid residue, or (ii) a mutant of a glucocorticoid receptor of a different mammalian species, said mutant of a glucocorticoid receptor of a different mammalian species differing from the corresponding wild type glucocorticoid receptor in that the lysine corresponding to position 419 of the human glucocorticoid receptor is replaced with a different amino acid residue. Preferably, lysine is replaced with alanine. It is shown in the examples that glucocorticoid receptor transactivation following glucocorticoid binding can be restored under ischemic conditions in cells transfected with the K426A mutant of the murine glucocorticoid receptor. Position 426 of the murine glucocorticoid receptor is the position corresponding to position 419 of the human glucocorticoid receptor. The sequences of SEQ ID NOs: 1 and 2 are those of the K419A mutant human glucocorticoid receptor (cDNA and amino acid sequence, respectively). The sequences of SEQ ID NOs: 3 and 4 are those of the K426A mutant murine glucocorticoid receptor (cDNA and amino acid sequence, respectively). The position of the lysine to be mutated in the glucocorticoid receptor of other species can be determined by the skilled person without further ado. In particular, the amino acid sequence of the glucocorticoid receptor of a given species may be aligned with the amino acid sequence of the human glucocorticoid receptor. The lysine aligning with the mutated position of the human sequence is the lysine to be mutated in the given species. Similarly, a multiple sequence alignment including human and/or murine glucocorticoid receptor sequences as well as sequences from one or more further species may be aligned. Algorithms for pairwise and multiple sequence alignment are known in the art. In brief, two nucleotide or protein sequences can be aligned electronically using suitable computer programs known in the art. Such programs comprise BLAST (Altschul et al. (1990), J. Mol. Biol. 215, 403-410), variants thereof such as WU-BLAST (Altschul & Gish (1996), Methods Enzymol. 266, 460-480), FASTA (Pearson & Lipman (1988), Proc. Natl. Acad. Sci. USA 85, 2444-2448) or implementations of the Smith-Waterman algorithm (SSEARCH, Smith & Waterman (1981), J. Mol. Biol. 147, 195-197). These programs, in addition to providing a pairwise sequence alignment, also report the sequence identity level (usually in percent identity) and the probability for the occurrence of the alignment by chance (P-value). Programs such as CLUSTALW (Higgins et al. (1994), Nucleic Acids Res. 22, 4673-4680) can be used to align more than two sequences. Preferably, default settings of the respective computer programs as published are used. A preferred alignment program is BLAST (loc. cit.).
The present invention furthermore relates to a method of treating or preventing an ischemic disorder of the central nervous system, comprising the step of administering to a patient suffering from or an individual at risk of developing an ischemic disorder of the central nervous system (a) an effective amount of at least one glucocorticoid; and an effective amount (ba) of at least one proteasome inhibitor and/or (bb) of at least one nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation.
Also provided is a method of treating or preventing glucocorticoid resistance in ischemic disorders of the central nervous system, comprising the step of administering to a patient suffering from or an individual at risk of developing glucocorticoid resistance in an ischemic disorder of the central nervous system an effective amount of at least one proteasome inhibitor and/or of at least nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation.
Preferred embodiments of the invention, said preferred embodiments being defined herein above, also define preferred embodiments of the above methods of treatment.
The Figures show:
cEND cells were plated at a density of 1.1*105 cells/3.5 cm2 dish and grown to confluence. At confluence, cells were maintained at 2% FCS and O2-deprivation or O2/glucose-deprivation and glucocorticoids as indicated. After reaching confluence, cells were subjected for 2 h, 4 h, 8 h and 16 h to O2-deprivation in the presence and absence of glucose followed by a reperfusion of 24 h under normoxia with standard DMEM medium containing 11% glucose for all time points. Cell viability was by assessed by the release of LDH in response to O2-deprivation or O2/glucose deprivation: after the individual time points, the cytotoxicity and plasma membrane lysis was determined by analysis of release of intracellular LDH from damaged cells as compared to cells maintained under normoxic conditions. LDH analysis was performed by using the colorimetric LDH activity assay (Cytotoxicity Detection Kit (Roche)). Long term O2/glucose deprivation increased plasma membrane damage significantly (P<0.02) more than O2 deprivation alone: after 2 h of O2- or O2/glucose-deprivation, cEND cells were damaged by 8.6±3.6% (O2-depr) and 10.66±2.13% (O2/glu depr), after 4 h of O2- or O2/glucose-deprivation relative cytotoxicity was increased by 15.51±1.1% (O2/glu depr) and 13.35±0.9% (O2-depr), and after 16 h of incubation under O2- or O2/glucose-deprivation, a relative cytotoxicity of 66.1±2.01% (O2/glu depr) and 29.62±3.1% (O2-depr) was determined.
(A) Glucocorticoid treatment does not restore compromised brain microvascular endothelial barrier function in response to O2/glucose-deprivation: under normoxic conditions 24 h dexamethsone treatment (100 nM) significantly (P<0.05) increased TER values from 371±59 Ωcm2 (normox) to 671±43 Ωcm2 (normox+dex). After O2/glucose-deprivation, measured TER of untreated cells was lowered to 195±47 Ωcm2 (O2/glu depr). Dexamethasone administration during reoxygenation (O2/glu depr+dex) did not increase TER values (167±39 Ωcm2) as opposed to the observations under normoxic conditions.
(B) Gene expression levels of genes encoding the BBB tight junction proteins occludin, claudins-3, -5, -12 and the adherens junction protein, VE-cadherin, were assessed by real time RT-PCR. We assessed gene induction by dexamethasone under nomoxic conditions or after O2/glucose deprivation. The validated GC target gene occludin was significantly (P<0.05) induced by dexamethasone under normoxic conditions. mRNA analyses revealed claudin-3 (P<0.001) and claudin-12 (P<0.05) as potential novel GR target genes in brain microvascular cEND cells. The genes for claudin-5 and VE-cadherin were on the contrary not induced by GC. After O2/glucose deprivation, induction of genes encoding occludin, claudin-3 and claudin12 by dexamethasone was abolished pointing to GC insensitivity after O2/glucose deprivation at the gene expression level. Normox control (black bars), normox+dex (white bars), O2/glu depr (light grey bars), O2/glu depr+dex (dark grey bars).
(C)-(D) The influence of O2/glucose-deprivation on the tight junction proteins occludin and claudin-5 could be shown by Western Blot: for this, cells were seeded on plastic cell culture flasks coated with collagen IV, treated as indicated and subjected to SDS-gel electrophoresis and Western blotting. A four-hour exposure to O2/glucose-deprivation caused a significant (P<0.05) decrease in occludin protein to 82±3% as compared to the untreated control. While in cEND cells maintained in normoxia, dexamethasone administration elevated occludin protein contents to 120±7%, treatment with dexamethasone after O2/glucose-deprivation did not recover occludin protein levels. After O2/glucose-deprivation we even detected a further decrease of occludin protein by dexamethasone administration to 57±5%, as compared to cells maintained in normoxia. Comparably, O2/glucose-deprivation caused a significant (P<0.001) decrease in claudin-5 protein to 61±4% as compared to the untreated control. Treatment with dexamethasone led to a slight increase in claudin-5 protein levels to 79±5%, as compared to untreated cells. Under normoxic conditions, dexamethasone administration did not significantly change claudin-5 contents as compared to untreated cells (110±7%) disclosing claudin-5 as a non-target for GC action.
(E) Densitometric evaluation of (c) and (d), normox control (gray bars), normox+dex (black bars), O2/glu depr (hatched bars), O2/glu depr+dex (striped bars).
(A) GR protein levels after O2/glucose-deprivation. Confluent monolayers of cEND cells were grown in collagen IV-coated cell culture flasks and exposed to normoxia or O2/glucosedeprivation in the presence and absence of 100 nM dexamethasone and 25 μM calpain inhibitor I as indicated. In cell lysates from control cEND cells (normox), there was a strong signal for GR protein detectable. 24 h of dexamethasone treatment (normox+dex) led to a ligand-dependent reduction to 66±2% reduction in detectable GR protein (n=3). In cEND cells exposed to O2/glucose-deprivation (O2/glu depr) GR protein was significantly (P<0.02) reduced to 26±3% of control (normox). 24 h of dexamethasone treatment during reoxygenation (O2/glu depr+dex), slightly induced GR levels to 40±4% of control (normox) cells as detected by WB and densitometric analysis. In contrast, O2/glucose deprivation in the presence of the proteasomal inhibitor calpain inhibitor I consistently and significantly (P<0.001) maintained GR protein levels at 84±2% of control (O2/glu depr calp Inh I) as compared to cells not treated with calpain inhibitor I (O2/glu depr). Additional dexamethasone treatment in the presence of calpain inhibitor I (O2/glu depr, calp Inh I+dex) led to liganddependent reduction of GR protein levels to 64±2% of the untreated cEND cells under NG conditions.
(B) GR transcriptional activation of a GC-responsive test promoter construct was monitored in normoxia and after O2/glucose-deprivation. Subconfluent cEND and Hek293 cells were cotransfected with reporters pMMTV-luc (2) and pRL-TK (Promega), then grown to confluence and exposed to conditions and dexamethsone-treated as indicated.
Cell extracts were assayed for Luc and Renilla activity. The transactivation activity without dexamethasone was considered as the baseline activity of the promoter.
While in Hek293 cells, MMTV promoter is transactivated by dexamethasone 26.45±4.8-fold in normoxia and 26.6.±5.3-fold after O2/glucose-deprivation (P<0.001) (n=4) by endogenous GR, in cEND cells, significantly reduced (P<0.05) transactivation by GR (3.7±2.6-fold) in endothelial cEND cells after O2/glucose-deprivation as opposed to transactivation in cEND cells in normoxia (29.01±3.2-fold) (normox+dex) was observed. Co-transfection of cEND cells with the mutant GR-K426A resistant to proteasomal degradation resulted in significantly (P<0.05) restored transactivation of the MMTV test promoter after O2/glucosedeprivation, (23.4±3.3-fold), which is comparable to GR transactivation activity of K426A-transfected cEND cells in normoxia (24.9±3.2-fold). The results are displayed as the ratio of activity with ligands to activity without (mean and s.d. from at least 4 experiments).
(A) Effects of dexamethasone on TER of cEND monolayers were detected in cEND cells transfected with the mutant GR-K426A defective for proteasomal degradation. Growth medium (10% FCS) was changed after 5 days in culture to differentiation medium (2° A FCS, ±additions) and analysis of the TER was performed after O2/glucose-deprivation as indicated. Treatment with 100 nM dex leads to an increase in TER to 671+43 Ωcm2 (normox+dex) (P<0.05) as compared to the untreated control (normox) (371+59 Ωcm2). After O2/glucose-deprivation, TER was reduced to 195+47 Ωcm2 (O2/glu depr) (P<0.05), and simultaneous treatment with dexamethasone (O2/glu depr+dex) did not lead to elevated resistances (166+39 Ωcm2). For GR-K426A-transfected cEND cells without dexamethasone administration (K426A O2/glu depr), O2/glucose-deprivation equally led to reduced TER (239+58 Ωcm2). As expected, treatment of K426A-transfected cells with dexamethasone (K426A O2/glu depr+dex) conditions led to full GC response as demonstrated by a significantly (P<0.05) increased TER (619±67 Ωcm2).
(B) At the mRNA level, transcripts of the glucocorticoid-responsive genes (occludin, claudin-12 and claudin-3) were significantly (P<0.01, occludin) upregulated in dexamethasone-treated cEND cells overexpressing the mutant K426A after O2/glucose-deprivation. Normox control (black bars), normox+dex (white bars), O2/glu depr (light grey bars), O2/glu depr+dex (dark grey bars), K426A, O2/glu depr (light dotted bars), K426A, O2/glu depr+dex (dark dotted bars)
(C) Effects of proteasomal inhibition on occludin protein levels were examined by western blot analysis and densitometric analysis. For this, GR-426A-transfected cEND cells were seeded on plastic cell culture flasks coated with collagen IV and subjected to O2/glucosedeprivation and treated with dexamethasone as indicated.
Mirroring observations at the mRNA level, O2/glucose-deprivation caused a decrease in occludin protein to 82±3% as compared to the untreated control and treatment with dexamethasone did not recover occludin loss, we detected a further decrease to 57±5% (P<0.05), as compared to cells in normoxia (normox). Introduction of the mutant GR-K426A led to an elevated significant (P<0.02) occludin protein synthesis when dexamethasonetreated after O2/glucose-deprivation (122±5%) (K426A O2/glu depr+dex) which was not observed without dexamethasone administration in cells after O2/glucose-deprivation (K426A O2/glu depr) (58±7%).
(D) Effects of proteasomal inhibition on claudin-5 protein levels O2/glucose-deprivation in the presence (44±11%) (K426A O2/glu depr+dex) and absence (41±8%) (K426A O2/glu depr) of dexamethasone in GR-K426A-transfected cEND cells led to a severe reduction in claudin-5 protein levels, which were even stronger than in the untransfected cEND cells after O2/glucose-deprivation (61±4%).
(E) Densitometric evaluation of (C) and (D), NG control (gray bars), NG+dex (black bars), HA/NG (hatched bars), HA/NG+dex (striped bars), K426A GR HA/NG (white bars), K426A GR HA/NG+dex (dotted bars)
A) Representative TTC stains (upper panel) of 3 corresponding coronal brain sections of mice untreated (Ctrl.), bortezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.) and mice treated with the combination of dexamethasone and bortezomib (Borte.+Dexa.). Brain infarct volumes (lower panel) as measured by planimetry in mice untreated (Ctrl.), bortezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.) and mice treated with the combination of dexamethasone and bortezomib (Borte.+Dexa.).
B) Neurological Bederson score (left panel) and grip test score (right panel) of mice (n=10/group) at day 1 after tMCAO in mice untreated (Ctrl.), bodezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.) and mice treated with the combination of dexamethasone and bortezomib (Borte.+Dexa.).
C. Representative corresponding coronal brain sections (upper panel) of mice untreated (Ctrl.), and mice untreated (Ctrl.), bortezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.) and mice treated with the combination of dexamethasone and bortezomib (Borte.+Dexa.) at day 1 after tMCAO after injection of Evans's blue. Note the strongly reduced edema volume in mice treated with the combination of dexamethasone and bodezomib (Borte.+Dexa.). Volume of Evans's blue extravasation (lower panel) determined by planimetry in the ischemic hemisphere of untreated untreated mice and mice treated with the combination of dexamethasone and bortezomib 24 hours after 60 minutes of tMCAO (n=4/group).
A) Representative TTC stains (upper panel) of 3 corresponding coronal brain sections of mice untreated (Ctrl.), bortezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.), methylprednisolone-treated mice (MP), cortisol-treated mice (HC) and mice treated with the combinations dexamethasone and bodezomib (Borte.+Dexa.), methylprednisolone and bodezomib (Borte+MP) and codisol and bodezomib (Bode+HC). Brain infarct volumes (lower panel) as measured by planimetry in mice untreated (Ctrl.), bodezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.) and mice treated with the combination of dexamethasone and bodezomib (Borte.+Dexa.).
B) Neurological Bederson score of mice (n=10/group) at day 1 after tMCAO in mice untreated (Ctrl.), bodezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.), methylprednisolone-treated mice (MP), codisol-treated mice (HC) and mice treated with the combinations dexamethasone and bortezomib (Borte.+Dexa.) methylprednisolone and bodezomib (Bode+MP) and codisol and bortezomib (Borte+HC).
C. Representative corresponding coronal brain sections (upper panel) of mice untreated (Ctrl.), bodezomib-treated mice (Bode.), dexamethasone-treated mice (Dexa.), methylprednisolonetreated mice (MP), cortisol-treated mice (HC) and mice treated with the combinations dexamethasone and bodezomib (Borte.+Dexa.), methylprednisolone and bortezomib (Borte+MP) and cortisol and bortezomib (Borte+HC) at day 1 after tMCAO after injection of Evans's blue. Note the strongly reduced edema volume in mice treated with the combination of dexamethasone and bortezomib (Borte.+Dexa.). Volume of Evans's blue extravasation (lower panel) determined by planimetry in the ischemic hemisphere of untreated untreated mice and mice treated with the combination of dexamethasone and bortezomib 24 hours after 60 minutes of tMCAO (n=4/group).
The database identifiers refer to the NCBI protein sequence database status of Sep. 18, 2009.
Effect of the administration of vehicle, bortezomib (“Borte”), dexamethasone (“Dex”) and a combination of Borte and Dex on neurological impairment.
The following examples illustrate the invention but should not be construed as being limiting.
Dexamethasone, methylprednisolone and cortisol and calpain inhibitor I (LLnL, N-acetyl-Leu-Leu-Nle-CHO) were purchased from Sigma, Taufkirchen, Germany.
Animal experiments were approved by the Regierung von Unterfranken and conducted according to the recently published recommendations for research in mechanism-driven basic stroke studies (Dirnagl (2006)).
Focal cerebral ischemia was induced in 6-8-weeks old mice by 60 min transient middle cerebral artery occlusion (tMCAO) as described (Kleinschnitz (2006)). Briefly, mice were anesthetized with 2.5% isoflurane (Abbott, Wiesbaden, Germany) in a 70% N2O/30% O2 mixture. Following a midline skin incision in the neck, the proximal common carotid artery and the external carotid artery were ligated and a standardized silicon rubber-coated 6.0 nylon monofilament (6021; Doccol Corp., Redlands, Calif., USA) was inserted and advanced via the right internal carotid artery to occlude the origin of the right MCA. Operators (TS, CK) were blinded to the treatment groups and operation time per animal did not exceed 15 minutes. The intraluminal suture was left in situ for 60 minutes. Then animals were re-anesthetized and the occluding monofilament was withdrawn to allow reperfusion. 2 h after reperfusion mice were treated with intraveneous injections of either dexamethasone (Sigma-Aldrich, Taufkirchen, Germany; 10 mg/kg), bortezomib (Janssen-Cilag GmbH, Neuss, Germany, 0.2 mg/kg) or the combination of both substances (n=10/group). Control mice (n=10) received 0.9% NaCl solution. Assessment of functional outcome, determination of infarct size and determination of brain edema volume were carried following standard procedures (Austinat (2009)).
For comparison of the efficacy of a combination therapy with bortezomib with either of two commonly used steroids in the clinical practise (dexamethasone and methylprednisolone, respectively) and of the endogenous GC cortisol, mice were treated with equivalent doses of the GC: dexamethasone (Sigma-Aldrich, Taufkirchen, Germany; 10 mg/kg), methylprednisolone (Sigma-Aldrich, Taufkirchen, Germany; 60 mg/kg) and cortisol (Sigma-Aldrich, Taufkirchen, Germany; 300 mg/kg) and bortezomib (Janssen-Cilag GmbH, Neuss, Germany, 0.2 mg/kg) or the combination of either GC with bortezomib (n=10/group). Control mice (n=10) received 0.9% NaCl solution. Assessment of functional outcome, determination of infarct size and determination of brain edema volume were carried following standard procedures (Austinat (2009)).
The immortalized mouse brain capillary endothelial cell line cEND was generated as described (Förster (2005)).
cEND cells were cultivated as described (Förster (2008)). Hek293 cells were maintained in DMEM, 10% FCS. For normoxic conditions (normox) cells were maintained in an atmosphere of 5.0% CO2/95% O2 and at 37° C. in DMEM, 2% FCS. For the establishment of O2/glucose deprivation conditions (O2/glu depr), cells were maintained in an atmosphere of 1% O2 balanced with N2 in glucose-free DMEM, 2% FCS for 4 h and reoxigenated in DMEM medium, containing 11% glucose, 2% FCS in an atmosphere of 5.0% CO2/95% O2 at 37° C. for 24 h for all experiments. We performed cell viability assays following standard procedures.
Electrophoresis and immunoblotting, quantitative real-time RT-PCR, transendothelial electrical resistance measurements, transfection and luciferase assay were performed following standard procedures.
Values for densitometry, gene expression and promoter transactivation were averaged to establish a single value for control cells and treated cells as indicated. Values were compared through analysis of variance (ANOVA) with Bonferroni post hoc test: P values <0.05 were considered significant (*).
The brain endothelium becomes rapidly activated during ischemic stroke and structural BBB damage can already be found several hours after stroke onset in rodents and humans (del Zoppo (2001), Rosenberg (2009)). GC, like the therapeutically administered dexamethasone, have been demonstrated to stabilize BBB integrity in many diseases like Multiple Sclerosis or in the adjuvant treatment of brain tumours, mainly by the induction of tight and adherens junction proteins as direct or indirect target genes (Förster (2007), Romero (2003), Blecharz (2008), Koehler (1995)). However, barrier tightening or preserving effects could not be observed in the treatment of stroke patients (3). To resolve the molecular basis for this obvious GC insensitivity or resistance under conditions of O2/glucose deprivation, we established in vitro conditions for O2/glucose deprivation utilizing our cEND in vitro model of the BBB (Förster (2005)). For the establishment of standardized stroke-like conditions, we first compared the extent of cellular damage by stroke-like conditions (O2/glucose deprivation) to the effects of exposure to O2-deprivation alone (
Analysis of GC effects on brain endothelial barrier integrity under normoxic and O2/glucose-deprived conditions revealed strong differences in GC efficacy. Exposure of cEND monolayers to O2/glucose deprivation compromised barrier tightness as reflected by a significant (P<0.05) decrease in TER, 195±47 Ωcm2 (O2/glu depr), as compared to control monolayers maintained under normoxic conditions, 371±59 Ωcm2 (normox) (
Alterations in barrier tightness are mainly reflected by the expression levels of tight junction proteins sealing the paracellular space (Förster (2008)). We compared gene expression levels between monolayers maintained under nomoxic conditions or after O2/glucose deprivation and after dexamethasone administration (
At first, expression levels of genes encoding the tight junction proteins occludin, claudins-3, -5, -12 and the adherens junction protein, VE-cadherin, were assessed by real time RT-PCR (
The tight junction proteins occludin and claudin-5 are described to be the key mediators of BBB sealing and maintenance (D'Atri (2002)). A measurable reduction in tight junction protein levels and lack in GC effects would establish the morphological correlate for the increased monolayer permeability detected. Therefore, we next assessed the effects of O2/glucose deprivation in the presence and absence of dexamethasone on occludin and claudin-5 protein levels (
Dexamethasone failed to induce an increase in levels of the GC target protein occludin after O2/glucose deprivation. GC effects at the protein level thus mirrored observations at the gene expression level, indicating that effects at the gene expression level are chiefly responsible for variances in barrier restoration by GC.
As expected, claudin-5 induction by dexamethasone was not observed under either condition ruling out claudin-5 as a directly regulated target of GC at the BBB (
In an effort to explain the lack of GC-sensitivity and -response of cEND cells exposed to O2/glucose deprivation, we compared GR protein levels in cEND cells maintained in the presence and absence of dexamethasone in normoxic conditions or after O2/glucose deprivation. We further determined GR activity by promoter-reporter gene assay (
The major biological function of steroid hormone receptors like GR is control of gene expression. To test whether the synergistic effect of proteasomal inhibition and dexamethasone administration would restore GR activity, we tested GR-mediated transactivation of a well described GC-responsive test promoter, MMTV (Benore-Parsons (1991)). The MMTV test promoter which contains five classical consensus GREs (5′-GTTACAnnnTGTTCT-3′) (Benore-Parsons (1991)) was introduced into cEND and HEK293 cells under the different experimental conditions. MMTV promoter transactivation under normoxic conditions in dexamethasone-treated cEND cells (29.01±3.2-fold) and Hek293 cells (26.45+4.8-fold), respectively, compared well to the literature (
We were able to reverse this loss of receptor activity by introduction of the mutant GR-K426A into cEND cells. The mutant GR-K426A is resistant to proteasomal targeting due to a point mutation at the position lysine-426 important for ubiquitin conjugation to the GR protein destined for degradation (Wallace (2001)). Under both normoxic and hypoxic conditions, cEND cells overexpressing the mutant GR-K426A showed comparable MMTV test promoter transactivation levels (
Analysis of the combined effects of GC administration and proteasome inhibition following O2/glucose deprivation was expanded to BBB integrity. Functional analyses included measurement of monolayer tightness (TER) and gene and protein expression analyses of cEND cells transfected with the GR-K426A mutant under the different experimental conditions. While O2/glucose deprivation led to a measurable decrease of TER in GR-K426A-transfected cells (239+58 Ωcm2) (K426A O2/glu depr), we detected a significant (P<0.05) positive increase in monolayer tightness in GR-K426A-transfected cells in response to dexamethasone administration following O2/glucose deprivation (619±67 Ωcm2), as observed for dexamethasone-treated cEND cells in normoxia (
The glucocorticoid-responsive genes (occludin, 1.82±0.15-fold, claudin-12, 2.4±0.3-fold, and claudin-3, 4.1±1.1-fold) (P<0.01, occludin) were strongly upregulated in GR-K426A-transfected cells exposed to O2/glucose deprivation to a magnitude comparable to levels detected in cEND cells maintained in normoxia (
Non-GR targets (claudin-5, VE-cadherin) were not influenced at the gene expression level (
We subsequently hypothesized that the dual approach of GC treatment under proteasomal inhibition might also be beneficial under hypoxia in vivo, e.g. following acute ischemic stroke in which BBB disruption and edema formation are detrimental pathophysiological events unresponsive to steroid treatment. Indeed, mice subjected to transient middle cerebral artery occlusion (tMCAO) and treated with a combination of dexamethasone and the proteasome inhibitor bortezomib 2 h after stroke onset developed significantly (P<0.05) smaller brain infarct volumes at day 1 compared to untreated controls (78.7±19.5 mm3 vs. 43.6±22.3 mm3) (
Then the mouse tMCAO model was used to compare the effects of two commonly used steroids for the treatment of tumour-associated brain edema (dexamethasone and methylprednisolone) and of the endogenous GC cortisol in combination therapy with bortezomib on stroke volume, edema volume and global neurological dysfunction caused by tMCAO (
In the experiment described in the following, mice were subjected to controlled cortical impact (CCI) in order to generate a traumatic brain injury. 30 minutes after CCI, vehicle, bortezomib, dexamethasone, and a combination of bortezomib and dexamethasone have been administered. Bortezomib has been administered at a concentration of 0.2 mg/kg and dexamethasone has been administered at a concentration of 10 mg/kg. 24 hours after the controlled cortical impact, the neurological severity score has been determined. As is known in the art, the neurological severity score is a measure of neurological impairment and is quantified on a scale from 0 (no impairment) to 10 (maximum impairment). When determining the neurological severity score, primarily the motoric activity is assessed (walking on a bar, false steps, search or foraging, respectively, behaviour and the like). As can be seen from the data presented in
Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 269:29860-29866.
| Number | Date | Country | Kind |
|---|---|---|---|
| 09012330.8 | Sep 2009 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2010/064500 | 9/29/2010 | WO | 00 | 6/6/2012 |
